ABM Industries' ABM Respiratory Care Raises $14.8 Million for Airway Clearance Innovations
- ABM Respiratory Care raised $14.8 million in Series B financing, surpassing its $12 million goal for airway clearance solutions.
- The funding will enhance commercialization of BiWaze® Clear, improving lung function and patient usability in respiratory therapy.
- ABMRC aims to transform respiratory care and patient outcomes with innovative technologies and better disease management strategies.
ABM Respiratory Care Secures $14.8 Million in Series B Financing to Enhance Airway Clearance Solutions
ABM Respiratory Care (ABMRC), a pioneering medical technology company focusing on airway clearance and ventilation solutions, successfully completes its Series B financing round, raising $14.8 million, exceeding its original goal of $12 million. This oversubscribed funding round is spearheaded by Peter Soderberg, ABMRC's Chairman and Managing Partner of Worthy Venture Resources, LLC, who notably increased his investment in the company. Additional significant contributions come from Blue Wave Capital, LLC, and other investors committed to advancing innovations in respiratory care. The substantial financial backing underscores investor confidence in ABMRC’s potential to transform patient outcomes in respiratory health.
CEO Greg Miller articulates that this new funding will play a pivotal role in expanding access to ABMRC's advanced respiratory therapy platform. The focus remains on improving the quality of life for individuals grappling with breathing difficulties. The capital raised will be primarily allocated toward the commercialization of BiWaze® Clear, the company’s cutting-edge airway clearance system designed for both hospital and home settings. This innovative device integrates multiple functionalities—including lung expansion, high-frequency oscillations, and aerosol delivery—into a compact, battery-operated design. The goal is to enhance lung function by facilitating mucus clearance and optimizing aerosol deposition deep within the lungs, which could significantly shorten therapy times and increase patient usability.
Soderberg emphasizes that his decision to deepen his investment stems from ABMRC’s demonstrated performance and successful execution with its initial devices. The company is dedicated to developing intelligent and clinically differentiated respiratory care solutions that not only improve oxygen exchange but also reduce aerosol emission exposure. By fostering better disease management, ABMRC aims to make a global impact on patient care, positioning itself as a leader in the respiratory technology sector. This funding milestone reflects a transformative step for ABMRC as it seeks to advance respiratory therapy and improve care for patients worldwide.
In addition to the Series B funding, ABMRC’s innovative approach to respiratory care aligns with increasing demand for advanced medical technologies that enhance patient outcomes. As the healthcare landscape evolves, the company’s commitment to integrating technology with patient-centric solutions could set a new standard in respiratory management.
The advancement of BiWaze® Clear not only emphasizes ABMRC’s innovative capabilities but also highlights the growing importance of effective airway clearance technologies in clinical practice. With this significant investment, ABMRC is well-positioned to lead the charge in enhancing respiratory care solutions that positively affect the health and well-being of patients globally.